- Just-launched gene editor Scribe Therapeutics will collaborate with Biogen (BIIB -0.5%) to develop and commercialize CRISPR-based therapies for the potential treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.
- Under the terms of the agreement, the parties will create therapies for genetically driven ALS with an option to pursue an additional neurological disease target with high unmet need. Scribe will receive $15M upfront, up to $400M in milestones between the two targets and tiered high single-digit-to-sub-teen royalties on net sales.
- Scribe was founded by former members of CRISPR pioneer Jennifer Doudna's lab at UC Berkeley, including Dr. Doudna herself. VC shop Andreessen Horowitz is an investor.
- https://seekingalpha.com/news/3620162-biogen-teams-up-scribe-therapeutics-to-develop-gene-therapy-for-als
Tuesday, October 6, 2020
Biogen teams up with Scribe Therapeutics to develop gene therapy for ALS
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.